Shares have corrected 55.8 per cent from their high earlier this year of $423.32 to $187.01 based on the Dec. 11 closing ...

In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...

So far five companies have agreed to the terms. They are Pfizer, Eli ​Lilly, AstraZeneca, Novo Nordisk and EMD Serono, which ...

Shares of Pfizer PFE dropped more than 3% on Tuesday after the company announced its financial outlook for the full year 2026 ...

Market sentiment has visibly soured. Year-to-date, the share price is down approximately 52%, and it has declined nearly 60% over a twelve-month period. The stock is trading close to its 52-week low, ...

History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

VanEck Pharmaceutical ETF is rated a Buy with stability, earnings visibility, and resilience across volatile market cycles.

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...

Available At Discount: At a P/S multiple of 11.0, V stock is currently offered at a 35% discount compared to one year ago.

Shares of Palantir Technologies traded slightly higher over the past month, a solid continuation of its exceptional year as the market’s premier artificial intelligence pure-play. The stock is ...

The bull market is not over, but it is changing. Two major brokers explain why selectivity and earnings matter more than ever ...